Yellowbird Diagnostics Inc.

yellowbirddx.com
Innovation Type:
Diagnostics
Cancer Type:
Multiple
Funding Stage:
Proof of Concept
Fund:
Prospects
Yellowbird Diagnostics' novel PET imaging tracer, NeuCaVis, is a radiofluorinated fructose molecule providing higher sensitivity and specificity than fluorodeoxyglucose (FDG), the current clinical gold standard PET contrast agent.

Related news

    CONNECT WITH FACIT

    Learn more about how we are driving made-in-Ontario oncology innovations reach the market.